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Background: Gentamicin is used as a therapeutic agent for Ménière’s disease because of its vestibulotoxicity
causing chemo-ablation of the vestibular sensory epithelia. Its use has increased in recent years. However, there is
still no consensus about the dose regimen of gentamicin in the treatment of Ménière’s disease. In this study two
different dose regimen treatment protocols are compared in a placebo controlled study design. The primary objective
is to quantify the treatment effect on dizziness, the secondary objective is hearing evaluation.
Methods: We performed a randomized, double-blind, placebo-controlled study in adults with unilateral Ménière’s
disease according to the AAO-HNS guidelines resistant to conservative medication. Three groups received four
injections, administered weekly (four intratympanic injections with 40 mg/mL gentamicin solution, two injections
gentamicin solution and two injections of placebo in random order, or four injections with placebo). Outcome
measures were the score on the Dizziness Handicap Inventory and pure tone audiometry (PTA). Intended follow-up
was 2 years.
Results: During follow-up one patient exceeded the accepted amount of hearing loss. Further, enrollment was very slow
(until 12 months between two patients) and new insights showed an apparent benefit of intratympanic gentamicin
treatment (ITG). Therefore we performed an unscheduled interim analysis which showed that PTA threshold shifts
reached the stopping criteria in two more patients. Because of this, this study was ended. Of the three patients with the
significant PTA threshold shift two were enrolled in the gentamicin group.
Conclusion: No conclusions can be drawn concerning doses regimens. Now that new publications have shown that
ITG treatment can be an effective and safe treatment, a placebo-controlled randomized controlled trial may not pass the
ethical committee because of these recent reports in literature. Still, a dose regimen study (without placebo) on
ITG treatment needs to be performed.
Trial registration: This trial was registered in The University Medical Center Utrecht/ Gelre hospital Apeldoorn.
Protocol ID: 07/343, EudraCT number 2006-005913-37.
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Ménière’s disease (MD) is an invalidating illness charac-
terized by attacks of vertigo with hearing loss, tinnitus,
and/or aural fullness of the affected ear. The exact origin
of this disease is not known, but it is generally accepted
that endolymphatic hydrops is the pathophysiological sub-
strate. Treatment, besides advises on living habits and diet,
exists of medication. This treatment gives unsatisfying
results in many cases. The natural course of this disease
often results in a decline of the sensitivity of the ves-
tibular peripheral system and progressive hearing loss
[1]. Gentamicin is an aminoglycoside antibiotic that is
applied systemically for serious infections. Some of the
adverse events of gentamicin treatment are vestibulotoxicity
and cochleotoxicity. A common feature of aminoglycoside
ototoxicity is that delayed hearing impairment can occur
after cessation of treatment. This delay is affected by differ-
ent factors and takes place at multiple levels. Aminoglyco-
sides enter the cochlea rapidly following administration
(systemic and intratympanic) and reach a plateau within
0.5 to 3 h after application. Clearance from peri- and
endolymph is slow and aminoglycosides persist in the
inner ear fluids and tissues long after the drug has been
removed from the blood by renal clearance. The drugs
may persist in the inner ear fluids for months after
treatment and this may account for delayed hair cell
degeneration.
For several reasons gentamicin is more vestibulotoxic
than cochleotoxic [2]. Intratympanic gentamicin treatment
(ITG) for control of vertigo has become popular world-
wide. In this treatment gentamicin solution is applied in
the middle ear with the aim of damaging the vestibular hair
cells with an intended result of a decrease (or disappearing)
of vertigo complaints while preserving hearing [1,3-6].
Several studies have been published about this topic.
These are mainly descriptive studies that used different
gentamicin concentrations and administration protocols.
Unambiguous in these publications is the high success
rate in reducing the number of vertigo attacks. However,
still obscure is the best treatment scheme and optimal
concentration of gentamicin. Two dose regimen protocols
are mostly used. One model uses a fixed number of ad-
ministrations (fixed dose regimen) and the other model
uses a titration regimen where gentamicin is administered
until attacks disappeared or other terms are reached
[3,7-13]. Different papers, including two meta-analyses,
showed that the degree in dizziness control is not related
to the amount of vestibular functional loss after ITG treat-
ment [7,10,11]. There are to date a few placebo-controlled
studies on this topic available; for example, the study by
Stokroos et al. (2004) [14] used a titration model and the
study by Postema et al. (2008) [15] used a fixed dose regi-
men. Although the studies used a different treatment
protocol, both studies demonstrated the efficacy ofgentamicin treatment for Ménière’s disease when com-
pared to placebo treatment. A weakness of these stud-
ies is the limited follow-up time. Stokroos et al. used a
follow-up period of 6 months and Postema et al. of
12 months. The advice of the Committee on Hearing and
Equilibrium of the American Association of Otolaryngol-
ogy - Head and Neck Surgery (1995) is to use a follow-up
of at least 24 months, taking into consideration the ex-
pected placebo effects (Committee on Hearing and Dis-
equilibrium, 1995). In this study we compare the efficacy
of two different administration protocols. One uses four
injections with gentamicin solution (40 mg/mL) versus
two injections with gentamicin solution (40 mg/mL), both
compared to placebo treatment. The main question is
whether ablation of the peripheral vestibular system (four
injections) gives a better clinical result than more subtle
damage to the peripheral vestibular system (two injec-
tions). Secondary outcome is the effect of treatment on
hearing. Numbers of injections are based on the studies
by Stokroos et al. (1.5 +/- 0.5 injections) and Postema et al.
(4 weekly injections). The fact that to date no placebo-
controlled dose efficacy study is available is an extra argu-
ment for a placebo group. We expect a better clinical result
after four injections with gentamicin solution.
Methods
The study was started in two hospitals, the University
Medical Center in Utrecht (UMC Utrecht) and Gelre
Hospital Apeldoorn. Before entering the study all patients
gave written informed consent for participation in the
study. Patients were eligible for the study if they had been
diagnosed as having unilateral Ménière’s disease according
to the 1995 AAO-HNS criteria: two or more spontaneous
episodes of vertigo each lasting 20 min or longer, sensori-
neural hearing loss documented audiometrically in the
diseased ear and the presence of tinnitus, and/or aural
fullness in this ear. Causes other than Ménière’s disease
were excluded by a diagnostic protocol, including vestibular
tests, MRI of the cerebellopontine angle, clinical history,
and physical examination. Other inclusion criteria were:
Ménière’s disease resistant to conservative medical treat-
ment executed longer than 6 months, (that is, Dizziness
Handicap Score of at least 30 points) and ability to provide
written informed consent. Patients had to have compro-
mised hearing on the affected side without fluctuations.
Exclusion criteria were ipsilateral middle ear pathology,
contralateral ear pathology or contralateral hearing loss,
allergy for aminoglycosides, or earlier treatment with
intratympanic gentamicin. After ITG treatment patients
were advised to visit the physiotherapist for, for example,
Cawthorn-Cooksey exercises or other patient-specific ex-
ercises. Approval of the study was granted by the medical
ethics testing committee (METC) of both the University
Medical Center Utrecht and Gelre Hospitals Apeldoorn
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For assignment of the participants a computer-generated
list of random numbers was used. Patients were random-
ized to one of three treatment groups. The three groups all
received four weekly intratympanic injections. Group 1 re-
ceived placebo injections (sterile NaCl 0.9% solution),
group 2 received two injections with gentamicin 40 mg/mL
and two injections with placebo in random order, and group
3 received four injections with gentamicin 40 mg/mL. After
treatment the intended follow-up period was 2 years. Three-
monthly questionnaires were taken by telephone. If there
was any problem the patients were free to contact one of
the researchers and all the time they were free to with-
draw from the study. At the end of the follow-up a last
audiogram, ENG, and the DHI questionnaire were taken.
Primary outcome parameter was the total score on the
Dizziness Handicap Inventory (DHI). The DHI is a stan-
dardized and validated questionnaire assessing impair-
ments due to dizziness [16-18]. It comprises 25 items,
leading to a score range from 0 to 100, with higher
scores indicating more perceived impairments. The sec-
ondary outcome parameter was hearing loss. Intended
follow-up was 2 years. Stopping criteria were the occur-
rence of SUSARs (Suspected Unexpected Serious Adverse
Reactions), one of which was an average hearing deterior-
ation of 30 dB or more over the frequencies of 500, 1,000,
2,000, and 4,000 Hz of the treated ear, or an average de-
terioration of 15 dB or more over the frequencies of 500,
1,000, 2,000, and 4,000 Hz at the contralateral ear. Harms
were reported following the CONSORT extension for
harms. During follow-up at the outpatient clinic, the au-
diograms of the patients were visually compared with the
former audiograms.
Statistical analysis
Power analysis (alfa at 5% and power at 80%) showed
that 16 patients per group were needed to show a clinic-
ally relevant difference of 12 points on the DHI scores
between the three groups [19]. The first interim analysisTable 1 Demographic, clinical, and treatment characteristics o
Characteristics Total
n = 15
Sex
Male 8 (53%)
Age (mean, (SD)) 64.8 (12.5)
Duration of MD in years (median (range)) 3 (0.1-19.6)
DHI 48.6 (20.0)
Averaged (0.5, 1, 2, 4 kHz) pure-tone-hearing loss (dB HL)
Right 41.2 (19.9)
Left 50.6 (23.7)was planned to be performed when 18 patients were
included.
DHI scores and hearing outcomes were compared be-
tween the three groups with non-parametric statistics, due
to the small numbers (Kruskal Wallis test for continuous
variables).
Results
Between June 2009 and January 2012 we included 15
patients. One patient was included in the UMC Utrecht
and 14 in Gelre Hospital. The time between inclusion
of the 14th and the 15th patient was 12 months. Mean
age was 64.8 years (SD 12.5 years), eight (57%) were
men. Five (one man) were randomized in group 1, five
(four men) in group 2, and five (three men) in group 3
(Table 1). However, one patient (group 2) withdrew
from the study after randomization. Although informed
consent was obtained before inclusion, she changed her
mind and did not want the chance to be treated with
placebo and was not included in the further follow-up
and analyses. Another patient withdrew from the study
after two injections because he suffered from Tumarkins
crises. One patient died during the study (as a result
of co-morbidity). This patient was enrolled in the
gentamicin-placebo group (group 2). The median dur-
ation in years of MD was 2.5 (range, 0.1 to 18.2) for
the placebo-group, 3.3 (range, 0.7 to 7.5) for the
placebo-gentamicin group, and 3.1 (range, 1.1 to 19.6)
for the gentamicin group. Because of the slow enroll-
ment, apparent hearing loss in one patient and new in-
sights with respect to the benefit of ITG treatment the
randomization code was broken and we performed an
unscheduled interim analysis on which the following
results are based.
Effect of treatment: vertigo
The median DHI score before treatment was 54 points
(range, 32 to 76), 44 points (range, 18 to 56), and 46
points (range, 20 to 88) for the placebo group, the
gentamicin-placebo group, and the gentamicin group,f included patients
Placebo Gentamicin/Placebo Gentamicin
n = 5 n = 4 n = 5
1 (20%) 4 (100%) 3 (60%)
57.3 (16.7) 72.6 (5) 64.5 (8)
2.5 (0.1-18.2) 3.3 (0.7-7.5) 3.1 (1.1-19.6)
54.0 (18.0) 40.5 (16.4) 51.2 (25.5)
35.0 (24.5) 29.7 (7.4) 59.0 (8.6)
43.8 (21.6) 61.3 (30.7) 46.8 (21.3)
Bremer et al. Trials 2014, 15:328 Page 4 of 6
http://www.trialsjournal.com/content/15/1/328respectively. At the time of the interim analysis the
median DHI score for the placebo group was 24 points
(range, 4 to 34, decrease of 20 points), for the
gentamicin-placebo group 34 points (range, 4 to 58,
decrease of 10 points), and for the gentamicin group 5
points (range, 0 to 76, decrease of 41 points); the latter
group showed the largest decrease in DHI score but
this was not statistically significant (P >0.5).
Side-effect of treatment: hearing outcome
During follow-up, one patient had a hearing loss of 50 dB
of the treated side averaged over the four frequencies
which was more than the criterium of 30 dB. The interim
analysis showed two more patients with a hearing loss of
more than 30 dB. Both had an exceeding of the accepted
threshold shift (30 dB) of approximately 5 dB. After break-
ing the randomization code, the patient with the PTA shift
of 50 dB was enrolled in the gentamicin group. Of the pa-
tients with the minor exceeding, one was also enrolled in
the gentamicin group and the other patient was enrolled
in the placebo group. The mean increase in PTA threshold
shift for the placebo group was 10 dB, for the gentamicin-
placebo group 0.9 dB and for the gentamicin group
27.4 dB (P >0.5).
Discussion
The present study was performed to assess a good dose
regimen protocol for ITG therapy in patients suffering
from Ménière’s disease. Unfortunately, no conclusive
statements can be made about this due to the fact that
the study was ended prematurely and at that time too
few patients have been included to make significant con-
clusions. However, our results indicate that there does
seem to be efficacy of gentamicin treatment in compari-
son to placebo but the significant risk for hearing loss
with four injections enervates these results.
The time between inclusion of the 14th patient and
15th patient was 12 months indicating a very slow enrol-
ment. During that time a Cochrane Review was pub-
lished which stated that ITG treatment was an effective
and safe therapy for patients with Ménière’s disease [6].
Also, a meta-analysis showed an effective and safe treat-
ment with intratympanic steroids [20]. Data monitoring
committees have an ethical obligation to ensure that pa-
tients are offered effective treatment as soon as it is clear
that an effective treatment is indeed available [21]. Based
on the slow enrollment, the suspicion of more hearing
loss besides the noticed exceeding in PTA shift of one
patient and together with the new scientific insights we
decided to perform the unscheduled interim analysis
over the 15 patients that had been included in our study
until that time. The results of this interim analysis
showed two other (minor) exceeding in PTA shift. This
meant that the stopping criterion was reached and thestudy was ended. Because of this unexpected stop of
the study full inclusion was not reached resulting in
too small a sample size to support a strong external
validity of our study. Clinicians should consider these
results with caution [22].
Retrospectively, visual determination of the audiograms
was not sufficient because two of the three exceedings of
the criteria for hearing loss were only noticed after the
unscheduled interim analysis. If, for example, the time
courses of hearing loss are calculated during outpatient
clinic visits, also a small exceeding in accepted hearing
loss is noticed. Two of the three patients were enrolled in
the gentamicin group so the PTA threshold shifts were
probably the result of the cochleotoxicity of gentamicin.
The third patient was enrolled in the placebo group so in
this case the MD itself instead of the ototoxicity of genta-
micin may have caused the PTA threshold shift; the nat-
ural course of Ménière’s disease eventually leads to a
sensorineural hearing loss of approximately 50 dB [1]. The
two patients of the gentamicin group are content with
their treatment as indicated by a strong reduced DHI
score. One other patient suffered from residual Ménière’s
attacks with Tumarkins crises after four injections and
withdrew from the study. This patient was enrolled in the
placebo group, so the cause of the crises was MD itself
and not gentamicin treatment. Subsequently, this patient
received one injection with gentamicin in the outpatient
clinic (outside the scope of this study) with satisfying re-
sults. We assessed the stopping criteria for hearing loss
for the PTA threshold shift at 30 dB averaged over the
four frequencies. Maybe some MD patients will accept the
chance of hearing loss as they are eager to be treated for
their main problem, that is, disabling vertigo attacks. So
maybe the determined stopping criterion for hearing loss
can be augmented in future studies.
The difficulty of recruiting enough Ménière subjects
for a 2-year follow-up period with adherence to the 1995
AAO-HNS guidelines for reporting is well known. There
is also a certain placebo effect when treating patients
with MD. This was the reason that this RCT contained a
placebo group. Frequently, this discouraged patients to
participate in the trial since they did not want to receive
placebo instead of gentamicin. These patients suffered
from recalcitrant MD, with a great morbidity, and they
demanded a ‘real’ treatment and did not accept the risk
to get treated with placebo. For this reason, studies have
been performed where two treatment modalities (for ex-
ample, intratympanic gentamicin vs. dexamethason or
prednison) are being compared [23,24]. The latter study
implicated less efficacy of prednison compared to ITG
injections without a difference in hearing level. A low-
dose protocol can be used [25-27], administrating just
one or two gentamicin injections with a similar effective-
ness for vertigo control and with a lower risk for major
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imbalance after treatment) as compared with high-dose
protocol [10]. But there are limitations on the latter study
regarding the variability in the total dosage of gentamicin
delivered (2.4 to 720 mg). Wasson et al. [28] indicated
efficacy of ITG also in the longer term (mean, 17 years
and 3 months).Conclusion
The known inherent risk of gentamicin treatment in-
duced hearing loss was also present in our study. Due to
a slow enrollment of patients into our study and recent
new clinical insights into the role and treatment benefits
of ITG in MD patients we terminated our study prema-
turely. We performed an interim analysis that revealed a
potential SUSAR that we reported to our Medical Eth-
ical Committee. This interim analysis did show some ef-
ficacy of four injections of gentamicin compared with
placebo. Important consideration beside its potential
benefit is the risk to perceptive hearing loss. To adapt a
placebo controlled study design, now that the reports in
literature show effectiveness for ITG seems unethical.
[6,20,28]. However, a randomized controlled trial on
dose regimens still has to be performed because of the
lack of consensus on the intratympanic dose of gentami-
cin that needs to be used to have the best balanced re-
sult between vertigo reduction and hearing preservation.Trial status
At the time of submission, 31% of the participants have
been included in the trial.Abbreviations
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